Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Read about the benefits and possible side effects of taking Jakafi® (ruxolitinib) for your intermediate or high risk myelofibrosis disease.

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi ® (ruxolitinib) (JAK-ah-fye) is a prescription medicine available as a pill. Jakafi is used to treat adults with intermediate or high-risk myelofibrosis (MF).

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Find information about myelofibrosis (MF) and Jakafi® (ruxolitinib), the first FDA-approved prescription medicine for adults with intermediate or high-risk myelofibrosis.

Learn about Jakafi® (ruxolitinib), a prescription medicine used to treat adults with polycythemia vera (PV) who have already taken hydroxyurea and it did not work well enough or they could …

Learn about Jakafi, an FDA-approved treatment for adults with PV, MF, aGVHD & cGVHD, and for 12 years & older pediatric patients with aGVHD & cGVHD.

Read about the benefits and possible side effects of taking Jakafi® (ruxolitinib). Jakafi is for adults with polycythemia vera (PV) who had already taken hydroxyurea and it did not work well …

Read about Jakafi® (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis (MF) in adults.